AR and neoplasm: The durable responses were unlikely to be due to re-response to enzalutamide monotherapy because patients either were progressing on enzalutamide immediately before trial entry or, if there was a treatment gap between trial entry and last ARSI, had tumours that expressed AR-V7, which associates with ARSI resistance37.